Glenmark Pharmaceuticals Ltd shares were trading 3.25% lower at ₹1,525.75 on the NSE as of 11:37 a.m. on November 13, 2024, as investors anticipated the company’s Q2 FY25 results. Expectations for Glenmark’s quarterly earnings include:
- Revenue: Projected at ₹3,426 crore, up from ₹3,207 crore YoY.
- EBITDA: Expected to be ₹635 crore, compared to ₹462 crore in the same period last year.
- EBITDA Margin: Estimated at 18.53%, an improvement from 14.41% YoY.
- Net Profit: Anticipated at ₹348 crore, a significant increase from ₹124 crore a year ago.
Investors await Glenmark’s earnings results to see if the company meets these expectations amidst recent market volatility.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
